|
122 Companies |
|
196 Products |
|
196 Products |
|
116 Mechanisms of Action |
|
3 Trials |
|
2338 News |
|
| «12...4567891011121314...4647» |
- || rivastigmine transdermal / Generic mfg.
Trial completion: Rivastigmine in the Management of Delirium (clinicaltrials.gov) - Jul 21, 2016
P3, N=23, Completed, Sponsor: Assistance Publique - Hôpitaux de Paris
Active, not recruiting --> Completed
- Trial completion, Trial primary completion date, Metastases: The Preventative Role of Exogenous Melatonin Administration in Patients With Advanced Cancer Who Are at Risk of Delirium: a Feasibility Study (clinicaltrials.gov) - Jul 20, 2016
P2, N=60, Completed, Sponsor: Bruyere Research Institute
Active, not recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Dec 2015 --> Apr 2016
- || osoresnontrine (BI 409306) / Boehringer Ingelheim
Trial primary completion date: Alzheimer Disease Proof of Concept Study With BI 409306 Versus Placebo (clinicaltrials.gov) - Jul 19, 2016
P2, N=288, Recruiting, Sponsor: Boehringer Ingelheim
Recruiting --> Completed | Trial primary completion date: Dec 2015 --> Apr 2016 Trial primary completion date: May 2017 --> Sep 2017
- Biomarker, Trial primary completion date: Down Syndrome Biomarker Initiative (DSBI) (clinicaltrials.gov) - Jul 19, 2016
P=N/A, N=12, Active, not recruiting, Sponsor: Alzheimer's Disease Cooperative Study (ADCS)
Trial primary completion date: May 2017 --> Sep 2017 Trial primary completion date: Jun 2016 --> Dec 2016
- AADvac1 / Axon Neurosci
Trial primary completion date: FUNDAMANT: 18-months Safety Follow-up Study of AADvac1, an Active Tau Vaccine for Alzheimer's Disease (clinicaltrials.gov) - Jul 19, 2016
P1, N=25, Active, not recruiting, Sponsor: Axon Neuroscience SE
Trial primary completion date: Jun 2016 --> Dec 2016 Trial primary completion date: May 2017 --> Aug 2016
- methylprednisolone sodium succinate / Generic mfg.
Surgery: Preoperative Single Glucocorticoid Hip Fracture Hip Fracture Surgery (clinicaltrials.gov) - Jul 18, 2016
P4, N=122, Completed, Sponsor: Hvidovre University Hospital
Trial primary completion date: May 2017 --> Aug 2016 Recruiting --> Completed
- ||||| idalopirdine (Lu AE58054) / Otsuka, Eli Lilly, Denovo
Enrollment closed: STARBRIGHT: Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With an Acetylcholinesterase Inhibitor (clinicaltrials.gov) - Jul 15, 2016
P3, N=734, Active, not recruiting, Sponsor: H. Lundbeck A/S
Recruiting --> Completed Recruiting --> Active, not recruiting
- ||||| idalopirdine (Lu AE58054) / Otsuka, Eli Lilly, Denovo
Enrollment closed: STARBEAM: Idalopirdine in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil (clinicaltrials.gov) - Jul 15, 2016
P3, N=858, Active, not recruiting, Sponsor: H. Lundbeck A/S
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||||| idalopirdine (Lu AE58054) / Otsuka, Eli Lilly, Denovo
Enrollment closed: STARSHINE: Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With Donepezil (clinicaltrials.gov) - Jul 15, 2016
P3, N=932, Active, not recruiting, Sponsor: H. Lundbeck A/S
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Enrollment open, Trial primary completion date: PACR-AD: Plasticity-based Adaptive Cognitive Remediation for Alzheimer Disease (clinicaltrials.gov) - Jul 15, 2016
P=N/A, N=40, Recruiting, Sponsor: Posit Science Corporation
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting | Trial primary completion date: May 2016 --> Sep 2016
- ||| Trial completion, Enrollment change, Trial primary completion date: Exploratory Study for the Validity of QuQu Scale (clinicaltrials.gov) - Jul 15, 2016
P=N/A, N=972, Completed, Sponsor: Translational Research Informatics Center, Kobe, Hyogo, Japan
Not yet recruiting --> Recruiting | Trial primary completion date: May 2016 --> Sep 2016 Recruiting --> Completed | N=400 --> 972 | Trial primary completion date: Dec 2015 --> Mar 2016
- Enrollment change: Sensory-cognitive and Physical Fitness Training in Mild Cognitive Impairment (clinicaltrials.gov) - Jul 15, 2016
P=N/A, N=65, Completed, Sponsor: University of Konstanz
Recruiting --> Completed | N=400 --> 972 | Trial primary completion date: Dec 2015 --> Mar 2016 N=100 --> 65
- | rivastigmine transdermal / Generic mfg.
Enrollment change: RIVET: Rivastigmine Patch in Veterans With Cognitive Impairment Following TBI (clinicaltrials.gov) - Jul 14, 2016
P3, N=96, Active, not recruiting, Sponsor: VA Office of Research and Development
N=100 --> 65 N=138 --> 96
- Enrollment closed, Enrollment change: Study of Retinal Findings in People With Signs and Symptoms of Alzheimer s Disease Enrolled in 09-M-0198 (clinicaltrials.gov) - Jul 14, 2016
P=N/A, N=33, Active, not recruiting, Sponsor: National Eye Institute (NEI)
N=138 --> 96 Recruiting --> Active, not recruiting | N=150 --> 33
- ||||||| dextromethorphan hydrobromide/quinidine sulfate / Generic mfg.
Trial completion: Safety Study of AVP-923 in the Treatment of IEED (Involuntary Emotional Expression Disorder) Also Known as Pseudobulbar Affect (Episodes of Uncontrolled Crying and/or Laughter) (clinicaltrials.gov) - Jul 12, 2016
P3, N=600, Completed, Sponsor: Avanir Pharmaceuticals
Recruiting --> Active, not recruiting | N=150 --> 33 No longer recruiting --> Completed
- |||| atabecestat (JNJ-54861911) / J&J
Trial completion, Phase classification: A Safety and Tolerability Study of JNJ-54861911 in Participants With Early Alzheimer's Disease (clinicaltrials.gov) - Jul 12, 2016
P2a, N=114, Completed, Sponsor: Janssen Research & Development, LLC
No longer recruiting --> Completed Active, not recruiting --> Completed | Phase classification: P2 --> P2a
- | donepezil / Generic mfg.
Trial completion, Adverse events: Donepezil and Vitamin E to Prevent Side Effects Caused By Radiation Therapy to the Head in Patients Receiving Treatment for Small Cell Lung Cancer (clinicaltrials.gov) - Jul 11, 2016
P3, N=9, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Active, not recruiting --> Completed | Phase classification: P2 --> P2a No longer recruiting --> Completed
- |||| rivastigmine / Generic mfg.
Trial completion: INSTINCT: 16w Interventional Study on Titration and Dose/Efficacy Assessment of Exelon in Chinese Alzheimer's Disease Patients (clinicaltrials.gov) - Jul 1, 2016
P4, N=221, Completed, Sponsor: Novartis Pharmaceuticals
No longer recruiting --> Completed Recruiting --> Completed
- Trial completion: Memory Training Versus Yogic Meditation Training in Older Adults With Mild Cognitive Impairment (clinicaltrials.gov) - Jun 30, 2016
P=N/A, N=66, Completed, Sponsor: University of California, Los Angeles
Recruiting --> Completed Active, not recruiting --> Completed
- Enrollment closed, Trial primary completion date: Brain Alterations and Cognitive Impairment in Older Adults With Heart Failure (clinicaltrials.gov) - Jun 23, 2016
P=N/A, N=40, Active, not recruiting, Sponsor: University of Wisconsin, Madison
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2016 --> Dec 2016
- Biomarker, Trial completion: A3PM: African American Alzheimer's Progression Markers - CSF and Neuro-Imaging (clinicaltrials.gov) - Jun 23, 2016
P=N/A, N=135, Completed, Sponsor: Emory University
Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2016 --> Dec 2016 Active, not recruiting --> Completed
- Trial completion, Trial primary completion date: Unrelated Hematopoietic Stem Cell Transplantation(HSCT) for Genetic Diseases of Blood Cells (clinicaltrials.gov) - Jun 23, 2016
P1/2, N=25, Completed, Sponsor: Children's Hospital Los Angeles
Active, not recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Aug 2012 --> Aug 2015
- Trial completion, Trial primary completion date: PET Imaging in Chronic Traumatic Encephalopathy (clinicaltrials.gov) - Jun 23, 2016
P=N/A, N=6, Completed, Sponsor: National Institute of Mental Health (NIMH)
Recruiting --> Completed | Trial primary completion date: Aug 2012 --> Aug 2015 Suspended --> Completed | Trial primary completion date: Sep 2016 --> Jun 2016
- Biomarker: Novel Retinal Imaging Biomarkers in Early Alzheimer's Disease (clinicaltrials.gov) - Jun 21, 2016
P=N/A, N=60, Active, not recruiting, Sponsor: Duke University
Suspended --> Completed | Trial primary completion date: Sep 2016 --> Jun 2016 Trial primary completion date: Sep 2016 --> Sep 2017
- Trial completion: Screening and Evaluation of Patients With Signs and Symptoms of Alzheimer's Disease (clinicaltrials.gov) - Jun 21, 2016
P=N/A, N=195, Completed, Sponsor: National Institute of Mental Health (NIMH)
Trial primary completion date: Sep 2016 --> Sep 2017 Suspended --> Completed
- ||||||| LMTX (hydromethylthionine) / TauRx
Trial completion: Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease (clinicaltrials.gov) - Jun 18, 2016
P3, N=800, Completed, Sponsor: TauRx Therapeutics Ltd
Suspended --> Completed Active, not recruiting --> Completed
- Enrollment closed, Trial primary completion date: Post-Operative Delirium in Elderly Surgical Patients (clinicaltrials.gov) - Jun 12, 2016
P=N/A, N=200, Active, not recruiting, Sponsor: Johns Hopkins University
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2016 --> May 2017
- Trial completion: DRIVE COG: Ability to Drive of Early Stage Alzheimer Disease (clinicaltrials.gov) - Jun 10, 2016
P=N/A, N=60, Completed, Sponsor: CHU de Reims
Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2016 --> May 2017 Not yet recruiting --> Completed
- Trial completion: Erythrocyte Complement Receptor 1 and Alzheimer Disease (clinicaltrials.gov) - Jun 10, 2016
P=N/A, N=200, Completed, Sponsor: CHU de Reims
Not yet recruiting --> Completed Recruiting --> Completed
- | Trial completion: Can Exercise Improve Cancer Associated Cognitive Dysfunction? (clinicaltrials.gov) - Jun 10, 2016
P2, N=31, Completed, Sponsor: University of British Columbia
Recruiting --> Completed Active, not recruiting --> Completed
- | BN82451 / Ipsen
Enrollment closed: Study Exploring Safety, Pharmacokinetic and Pharmacodynamic of BN82451 in Male Huntington's Disease Patients (clinicaltrials.gov) - Jun 1, 2016
P2a, N=30, Active, not recruiting, Sponsor: Ipsen
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Trial completion: PEARL-HD: [PETDE10] Imaging of PDE10A Enzyme Levels in Huntington's Disease Gene Expansion Carriers and Healthy Controls With PET. (clinicaltrials.gov) - Jun 1, 2016
P0, N=90, Completed, Sponsor: CHDI Foundation, Inc.
Recruiting --> Active, not recruiting Recruiting --> Completed
- Trial primary completion date: 18F-AV-1451 High Resolution Autopsy Study (clinicaltrials.gov) - May 31, 2016
P1, N=10, Recruiting, Sponsor: Avid Radiopharmaceuticals
Recruiting --> Completed Trial primary completion date: Nov 2016 --> Jun 2017
- Trial completion, Phase classification, Enrollment change, Trial primary completion date: Bioavailability of Ubiquinol in Huntington Disease (clinicaltrials.gov) - May 27, 2016
P1, N=6, Completed, Sponsor: University of Rochester
Trial primary completion date: Nov 2016 --> Jun 2017 Recruiting --> Completed | Phase classification: PN/A --> P1 | N=12 --> 6 | Trial primary completion date: Mar 2010 --> Jul 2012
- Enrollment closed: Physical Activity and Neuropsychological Outcomes in a Cancer Population (clinicaltrials.gov) - May 27, 2016
P=N/A, N=87, Active, not recruiting, Sponsor: University of California, San Diego
Recruiting --> Completed | Phase classification: PN/A --> P1 | N=12 --> 6 | Trial primary completion date: Mar 2010 --> Jul 2012 Recruiting --> Active, not recruiting
- ||||||| Trintellix (vortioxetine) / Lundbeck, Takeda
Trial completion, Trial primary completion date: Efficacy of Vortioxetine on Cognitive Dysfunction in Patients With Partial or Full Remission of Major Depressive Disorder (clinicaltrials.gov) - May 27, 2016
P3, N=151, Completed, Sponsor: H. Lundbeck A/S
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> Apr 2016
- Trial termination: Music Therapy in Alzheimer's Disease (clinicaltrials.gov) - May 26, 2016
P=N/A, N=35, Terminated, Sponsor: University Hospital, Toulouse
Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> Apr 2016 Completed --> Terminated
- | Trial completion, Enrollment change: OculoMacl: Oculomotor Testing in the Differential Diagnosis of Dementia (clinicaltrials.gov) - May 24, 2016
P3, N=65, Completed, Sponsor: Assistance Publique - Hôpitaux de Paris
Completed --> Terminated Active, not recruiting --> Completed | N=100 --> 65
- || donanemab (LY3002813) / Eli Lilly
Trial primary completion date: A Study of LY3002813 in Participants With Alzheimer's Disease (clinicaltrials.gov) - May 23, 2016
P1, N=100, Active, not recruiting, Sponsor: Eli Lilly and Company
Active, not recruiting --> Completed | N=100 --> 65 Trial primary completion date: Sep 2016 --> Jan 2017
- Licensing / partnership, Enrollment change: Partners in Dementia Care: A Telephone Care Consultation Intervention Provided to Veterans in Partnership With Local Alzheimer's Association Chapters (clinicaltrials.gov) - May 20, 2016
P=N/A, N=994, Completed, Sponsor: VA Office of Research and Development
Trial primary completion date: Sep 2016 --> Jan 2017 N=508 --> 994
- Trial completion, HEOR: Effect of VSL#3 (Original De Simone Formulation) on Cognitive Function, Risk of Falls and Quality of Life in Patients With Cirrhosis (clinicaltrials.gov) - May 20, 2016
P4, N=40, Completed, Sponsor: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
N=508 --> 994 Recruiting --> Completed
- Trial termination: MK0952 in Patients With Mild-to-Moderate Alzheimer's Disease (0952-004)(COMPLETED) (clinicaltrials.gov) - May 17, 2016
P2, N=24, Terminated, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Completed Completed --> Terminated
- lisdexamfetamine / Generic mfg.
Enrollment change, Trial withdrawal, Trial primary completion date: LDX for the Treatment of Cognitive Functioning Issues in Women Post-Oophorectomy (clinicaltrials.gov) - May 13, 2016
P=N/A, N=0, Withdrawn, Sponsor: University of Pennsylvania
Completed --> Terminated N=20 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Oct 2017 --> Dec 2013
- Enrollment closed, Trial primary completion date: CBTAC: Cognitive-Behavioral Treatment for Mild Alzheimer's Patients and Their Caregivers (clinicaltrials.gov) - May 13, 2016
P2, N=50, Active, not recruiting, Sponsor: University of Zurich
N=20 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Oct 2017 --> Dec 2013 Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2016 --> Sep 2017
- Enbrel (etanercept) / Pfizer, Amgen
Trial completion: Short Term Efficacy and Safety of Perispinal Administration of Etanercept in Mild to Moderate Alzheimer's Disease (clinicaltrials.gov) - May 13, 2016
P1, N=12, Completed, Sponsor: Life Extension Foundation Inc.
Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2016 --> Sep 2017 Active, not recruiting --> Completed
- Enrollment closed: Memory Training Versus Yogic Meditation Training in Older Adults With Mild Cognitive Impairment (clinicaltrials.gov) - May 13, 2016
P=N/A, N=66, Active, not recruiting, Sponsor: University of California, Los Angeles
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||| Biomarker, Trial completion, Trial primary completion date: ADDM: Alzheimer's Disease Biomarkers in Cerebrospinal Fluid in Insulin-resistant Men (clinicaltrials.gov) - May 13, 2016
P=N/A, N=58, Completed, Sponsor: University of Eastern Finland
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | Trial primary completion date: Dec 2015 --> Apr 2016
- Trial completion: 4-question "RACY" Delirium Screening Tool Validation Study (clinicaltrials.gov) - May 13, 2016
P=N/A, N=1093, Completed, Sponsor: University of Cape Town
Active, not recruiting --> Completed | Trial primary completion date: Dec 2015 --> Apr 2016 Active, not recruiting --> Completed
- Enrollment closed, Enrollment change: Actigraphy to MEasuRe Intensive Care Unit Activity (clinicaltrials.gov) - May 12, 2016
P=N/A, N=25, Active, not recruiting, Sponsor: Vanderbilt University
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=75 --> 25
- Trial primary completion date: Energy Metabolism and Cognitive Aging (clinicaltrials.gov) - May 12, 2016
P4, N=40, Recruiting, Sponsor: University of Cincinnati
Recruiting --> Active, not recruiting | N=75 --> 25 Trial primary completion date: Dec 2015 --> Dec 2016